Lexicon made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers.
3 months ago

(Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a private...
1 month ago

Lexicon is hoping for an approval that clears the drug to be used as an add-on to insulin therapy for adults with Type 1 diabetes mellitus and...
1 month ago

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
1 month ago

The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's drug for a broad treatment of heart failure,...
11 months ago

Lexicon Pharmaceuticals Inc (LXRX) is higher by Wednesday morning, with the stock rising 2.39% in pre-market trading to 3.
2 months ago

As of Feb. 15, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key...
2 months ago

Insiders who bought Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) stock in the last 12 months were richly rewarded last...
2 months ago

Vinson & Elkins advised Lexicon Pharmaceuticals, Inc. in the completion of a public offering and concurrent private placement of shares of...
10 months ago

Lexicon aims to significantly increase market access coverage in the first half of 2024 and expects continued prescription and net sales growth...
3 months ago